Ongericimab

Intervention1 paper3 findings

Outcomes

3

Treatment-emergent adverse events

no changein humans1RR 1.01High certainty

1 study

Ongericimab has no effect on treatment-emergent adverse events in humans (RR 1.01; 0.90-1.14).
Reviewdyslipidemia
Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment · Cardiology in review · 11 Sep 2026

Apolipoprotein B

downin humans1High certainty

1 study

Ongericimab decreases Apolipoprotein B in humans (-60.68).
Reviewdyslipidemia12 weeks
Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment · Cardiology in review · 11 Sep 2026

Apolipoprotein B →

LDL cholesterol

downin humans1High certainty

1 study

Ongericimab decreases LDL cholesterol in humans (-69.39 percentage points (95% CI, -73.67 to -65.11)).
Reviewdyslipidemia12 weeks
Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment · Cardiology in review · 11 Sep 2026

LDL cholesterol →

Latest

1

Cardiology in ReviewReview11 Sep

Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment